Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceralasertib Plus Durvalumab in Advanced or Metastatic NSCLC
NCT05941897Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ceralasertib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jun 2023; status: active, not recruiting.
02
Drugs
ceralasertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05941897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05941897.